CTRP3 and Progranulin in Patients With Coronary Artery Disease

Korea University

Status: Completed

Conditions: Coronary Artery Disease

Study type: Observational

Funder types: Other

Identifiers

NCT01869816

CAD(CTRP3,PRGL)

Details and patient eligibility

About

Visceral obesity is the one of the major causes of cardiovascular morbidity and mortality in industrialized countries. Adipose tissue secretes various kinds of bioactive molecules termed adipokines which contribute to the development of obesity-related disorders including cardiovascular disease (CVD). Progranulin and CTRP3 are recently discovered novel adipokines. Therefore, the investigators tried to compare circulating CTRP-3 and progranulin levels in patients with CAD and investigated whether CTRP-3 or progranulin is significantly associated with CAD prevalence after adjustment for well-known CAD risk factors.

Full description

CTRP-3 (synonyms CORS-26, cartducin and cartonectin) is a potent anti-inflammatory adipokine that inhibits proinflammatory pathways in monocytes and adipocytes. Using a recently developed enzymelinked immunosorbent assay (ELISA), we reported that circulating CTRP-3 levels were elevated in patients with glucose metabolism dysregulation.

Progranulin was identified as a key adipokine mediating high fat diet-induced insulin resistance and obesity through interleukin-6 (IL-6) in adipose tissue. We previously reported that progranulin levels were significantly higher in individuals with type 2 diabetes and were associated with macrophage infiltration in omental adipose tissue. Moreover, the expression of progranulin reduces inflammation and its degradation into granulins peptides enhances inflammation in atherosclerotic plaque, which may contribute to the progression of atherosclerosis There has been no previous report on the implication of CTRP-3 or progranulin in humans with cardiovascular disease (CAD). In the present study, we compared circulating CTRP-3 and progranulin levels in patients with CAD and investigated whether CTRP-3 or progranulin is significantly associated with CAD prevalence after adjustment for well known CAD risk factors.

Enrollment: 362 patients

Sex: All

Ages: 20 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• acute myocardial infarction
• unstable angina
• stable angina pectoris

Exclusion criteria

For control group, we exclude the participants who had

• a history of CVD (myocardial infarction, unstable angina, stroke, or cardiovascular revascularization)
• type 2 diabetes
• stage 2 hypertension (resting blood pressure, ≥160/100 mmHg)
• malignancy
• severe renal or hepatic disease

Trial design

362 participants in 3 patient groups

Acute coronary syndrome (ACS)

Description:

Who were admitted to the coronary care units of the division of cardiology at Guro hospital in Korea University Medical Center. They have Acute myocardial infarction or unstable angina.

Stable angina pectoris (SAP)

Description:

Who were admitted to the coronary care units of the division of cardiology at Guro hospital in Korea University Medical Center. They have Stable angina.

Control

Description:

Who were recruited from the participants for a routine health check-up in the Health Promotion Center of Korea University Guro Hospital.